Description: Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. It develops small molecule drug candidates primarily engineered to impact muscle function and contractility. The company's drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. The company has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Home Page: www.cytokinetics.com
350 Oyster Point Boulevard
South San Francisco,
CA
94080
United States
Phone:
650 624 3000
Officers
| Name | Title |
|---|---|
| Mr. Robert I. Blum | CEO, President & Director |
| Mr. Robert C. Wong | VP & Chief Accounting Officer |
| Dr. Fady Ibraham Malik FACC, M.D., Ph.D. | Executive Vice President of Research & Development |
| Mr. Andrew M. Callos | Executive VP & Chief Commercial Officer |
| Dr. James A. Spudich Ph.D. | Co-Founder & Member of Scientific Advisory Board |
| Mr. Sung H. Lee | Executive VP & CFO |
| Mr. Jeff Lotz | Vice President of Sales & Operations |
| Mr. Matt Yang | Vice President of Corporate Finance and Financial Planning & Analysis |
| Mr. Steven M. Cook J.D. | Senior Vice President of Global Supply Chain Operations & Technical Operations |
| Ms. Kari K. Loeser J.D. | VP & Chief Compliance Officer |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 60.2264 |
| Price-to-Sales TTM: | 1757.7473 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 423 |